Aclidinium/formoterol [1], antihistamines ---> SmPC of [1] of EMA
Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval because the action of formoterol on the cardiovascular system may be potentiated
Alcohol, antihistamines ---> SmPC of [mequitazine] of eMC
Antihistamines potentiate the sedative effects of alcohol
Alizapride, antihistamines
Increased CNS depressant effect
Alprazolam [1], sedating antihistamines ---> SmPC of [1] of eMC
Se puede producir una potenciación del efecto depresor sobre el SNC al administrar concomitantemente alprazolam con otros depresores del SNC
Amezinium, antihistamines
Enhancement of sympathomimetic effect
Aminoglycoside antibiotics, antihistamines
Antihistaminics may mask the ototoxic effects of other drugs
Amisulpride [1], sedating antihistamines ---> SmPC of [1] of eMC
Caution is advised when coadministering amisulpride with CNS depressants
Amitriptyline [1], antihistamines ---> SmPC of [1] of eMC
Increased anticholinergic and sedative effects. The concomitant use should be done with caution
Anticholinergics, antihistamines
Anticholinergic drugs associated with antihistaminics may have an additive antimuscarinic effect, which increases the risk of worsening glaucoma or urinary retention.
Antihistamines, antimuscarinic agents
The use of antimuscarinics will increase the risk of antimuscarinic side effects when used in conjunction with antihistamines.
Antihistamines, anxiolytics
Antihistamines potentiate the sedative effects of anxiolytics
Antihistamines, atropine [2] ---> SmPC of [2] of eMC
Combination of atropine with other drugs with anticholinergic activity may increase the risk of atropinic adverse effects (urinary retention, constipation, dry mouth).
Antihistamines, barbiturates
The co-administration may increase the CNS depressant effect
Antihistamines, beclometasone/formoterol/glycopyrronium [2] ---> SmPC of [2] of EMA
Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias.
Antihistamines, betahistidine
As betahistine is an analogue of histamine, interaction of betahistine with antihistamines may in theory affect the efficacy of one of these drugs.
Antihistamines, betahistine [2] ---> SmPC of [2] of eMC
Betahistine is a histamine analogue, concurrent administration of H1 antagonists may cause a mutual attenuation of effect of the active agents.
Antihistamines, biperiden
The combination of biperiden with other anticholinergic medicinal products may enhance the central and peripheral adverse reactions
Antihistamines, bornaprine
The co-administration of bornaprine with other anticholinergic drugs may enhance the central and peripheral adverse effects
Antihistamines, bromhexine
Bronchial secretion inhibitors may antagonize the effects of bromhexine
Antihistamines, brovanexine
The concomitant use of brovanexine and drugs that inhibit the bronchial secretions is not recommended
Antihistamines, buprenorphine [2] ---> SmPC of [2] of EMA
This combination increases central nervous system depression.
Antihistamines, buspirone [2] ---> SmPC of [2] of eMC
Antihistamines may enhance any sedative effect.
Antihistamines, butylscopolamine [2] ---> SmPC of [2] of eMC
The anticholinergic effect may be intensified by hyoscine butylbromide
Antihistamines, caffeine
Caffeine antagonizes the sedative effects of many substances, e.g. antihistamines.
Antihistamines, carboplatin ---> SmPC of [doxylamine] of eMC
Antihistaminics may mask the ototoxic effects of other drugs
Antihistamines, certoparin
The co-administration may weaken the pharmacological effects of certoparin
Antihistamines, chloroquine ---> SmPC of [doxylamine] of eMC
Antihistaminics may mask the ototoxic effects of other drugs
Antihistamines, chlorpromazine [2] ---> SmPC of [2] of eMC
The co-administration may increase the CNS depressant effect
Antihistamines, chlorprothixene
The co-administration of chlorprothixene with CNS depressants may cause strong sedation or respiratory depression
Antihistamines, cisplatin [2] ---> SmPC of [2] of eMC
Simultaneous use of cisplatin and antihistamines may mask ototoxicity symptoms (such as dizziness and tinnitus).
Antihistamines, clomipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Antihistamines, clozapine [2] ---> SmPC of [2] of eMC
Clozapine may enhance the central effects of CNS depressants
Antihistamines, CNS depressants
Antihistamines may have additive effects with other CNS depressants
Antihistamines, codeine [2] ---> SmPC of [2] of eMC
Enhanced sedative and hypotensive effect, increased risk of respiratory depression
Antihistamines, corticorelin
The co-administration of corticorelin with medicinal products that can inhibit its effect should be avoided
Antihistamines, cyclopentolate
The effects of antimuscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties
Antihistamines, dalteparin [2] ---> SmPC of [2] of eMC
A reduction of the anticoagulant effect may occur with concomitant administration of dalteparin with antihistamines
Antihistamines, dextromethorphan
The co-administration of dextromethorphan with CNS depressants can result in mutual potentiation of effects
Antihistamines, dihexazin
The co-administration may enhance the effects of other antihistaminic agents
Antihistamines, dimethindene
The sedative effect of CNS depressant drugs may be enhanced
Antihistamines, distigmine
The co-administration may antagonize the muscarinic effects of distigmine
Antihistamines, ebastine
Ebastine may enhance the effects of other antihistaminic agents
Antihistamines, enoxaparin
The co-administration may weaken the effect of enoxaparin
Antihistamines, erythromycin ---> SmPC of [doxylamine] of eMC
Antihistaminics may mask the ototoxic effects of other drugs
Antihistamines, ethyl loflazepate
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Antihistamines, etilefrine
The co-administration may increase the effect of etilefrine
Antihistamines, fluphenazine [2] ---> SmPC of [2] of eMC
Phenothiazines may increase the central nervous system depression produced by other CNS depressants
Antihistamines, formoterol [2] ---> SmPC of [2] of eMC
Caution should be observed in patients treated with drugs that may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia
Antihistamines, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA
Concomitant treatment can prolong the QT interval and increase the risk of ventricular arrhythmias.
Antihistamines, heparin
Possible decrease of anticoagulant effect of heparin
Antihistamines, histamine
Possible decrease of histamine efficacy
Antihistamines, histamine dihydrochloride [2] ---> SmPC of [2] of EMA
H1 receptor blocking antihistamines or neuroleptics (anti-psychotics) with H1 receptor blocking properties that might decrease efficacy of histamine dihydrochloride should be avoided.
Antihistamines, hyaluronidase
Inhibition of hyaluronidase
Antihistamines, hydrocodone
The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects
Antihistamines, hypnotics
Antihistamines potentiate the sedative effects of hypnotics
Antihistamines, IMAOs
The co-administration of dimetindene and MAO inhibitors may enhance the antimuscarinic and CNS depressant effects of antihistaminics. The co-administration is not recommended
Antihistamines, imipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Antihistamines, iopamidol
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Antihistamines, ketotifen [2] ---> SmPC of [2] of eMC
Ketotifen may potentiate the effects of antihistamines
Antihistamines, levomepromazine
The co-administration of levomepromazine with other central nervous depressants will cause a greater depressant effect on central nervous system
Antihistamines, lofepramine
Lofepramine may potentiate the effects of anticholinergic drugs on the central nervous system, eye, bowel and bladder.
Antihistamines, lorazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if lorazepam is combined with other CNS depressants
Antihistamines, maprotiline
The combination of maprotiline with anticholinergic agents may potentiate the central and peripheral effects (especially delirium)
Antihistamines, mefloquine
Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.
Antihistamines, melperone
An enhancement of the central depressive effect may occur in cases of combination of melperone with other central depressive drugs
Antihistamines, methantheline
Methantheline may enhance the anticholinergic effect of the antihistaminic agent
Antihistamines, midodrine
The co-administration may cause pronounced hypertension. The combination should be avoided
Antihistamines, mirtazapine [2] ---> SmPC of [2] of eMC
Mirtazapine may potentiate the sedative effects. Caution is recommended
Antihistamines, morphine [2] ---> SmPC of [2] of eMC
Medicinal products that block the action of acetylcholine may interact with morphine sulphate to potentiate anticholinergic adverse events.
Antihistamines, nadroparin
The co-administration may weaken the nadroparin effect
Antihistamines, neuroleptics
Antihistaminics enhance the anticholinergic effect
Antihistamines, noradrenaline ---> SmPC of [norepinephrine] of eMC
Some antihistaminics may block the catecholamine uptake by peripheral tissues and increase the toxicity of the injected noradrenalin
Antihistamines, norepinephrine
Some antihistaminics may block the catecholamine uptake by peripheral tissues and increase the toxicity of the injected noradrenalin
Antihistamines, nortriptyline [2] ---> SmPC of [2] of eMC
Supervision and adjustment of dosage may be required when nortriptyline is used with other anticholinergic drugs.
Antihistamines, opioid analgesics
Antihistamines potentiate the sedative effects of opioid analgesics
Antihistamines, oral anticoagulants
The antihistaminic agent may decrease the effect of oral anticoagulant
Antihistamines, ototoxic agents ---> SmPC of [doxylamine] of eMC
Antihistaminics may mask the ototoxic effects of other drugs
Antihistamines, oxomemazine
Enhancement of central anticholinergic effect
Antihistamines, oxybutynine [2] ---> SmPC of [2] of EMA
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity
Antihistamines, oxycodone [2] ---> SmPC of [2] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
Antihistamines, pentoxyverine
The use of CNS-depressors may enhance the sedative and respiratory depressive effects
Antihistamines, perphenazine
Risk of sedation and/or toxicity when perphenazine is administered with CNS depressants
Antihistamines, phenothiazines
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Antihistamines, piperidolate
The co-administration may increase the risk of adverse effects, e.g. paralytic ileus, retention of urine and blurred vision
Antihistamines, pitolisant [2] ---> SmPC of [2] of EMA
Anti-histamines (H1-receptor antagonists) crossing the haemato-encephalic barrier (e.g. pheniramine maleate, chlorpheniramine, diphenhydramine, promethazine, mepyramine) may impair the efficacy of pitolisant.
Antihistamines, pizotifen [2] ---> SmPC of [2] of eMC
The central effects of antihistamines may be enhanced by pizotifen.
Antihistamines, procarbazine
The co-administration of procarbazine and antihistaminics drugs should be done with caution in order to minimize a CNS depressor effect and a possible potentiation
Antihistamines, procyclidine [2] ---> SmPC of [2] of eMC
Drugs with anticholinergic properties may increase the anticholinergic action
Antihistamines, promethazine
The co-administration of promethazine and other central nervous depressants can mutually enhance the effects and adverse reactions (particularly sedation and hypotension)
Antihistamines, propantheline
Increased risk of antimuscarinic side effects when antimuscarinics are given with antihistamines.
Antihistamines, pyridostigmine
The antihistaminic agent antagonizes the muscarinic effects of pyridostigmine
Antihistamines, risperidone [2] ---> SmPC of [2] of eMC
Risperidone should be used with caution in combination with antihistaminics due to the increased risk of sedation
Antihistamines, scopolamine
Scopolamine may enhance the anticholinergic effect
Antihistamines, sodium heparin
Possible decrease of anticoagulant effect of heparin
Antihistamines, sodium iodide
The withdrawal period prior to administration of sodium [131I]iodine is 1 week
Antihistamines, tapentadol [2] ---> SmPC of [2] of eMC
The co-administration may enhance the sedative effect of tapentadol
Antihistamines, temazepam
Enhancement of the central depressive effect may occur if temazepam is combined with sedative antihistamines
Antihistamines, thalidomide [2] ---> SmPC of [2] of EMA
Thalidomide has sedative properties thus may enhance the sedative effects of other medicinal products
Antihistamines, thioridazine
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Antihistamines, tocofersolan [2] ---> SmPC of [2] of EMA
Due to inhibition of P-Glycoprotein transporter, tocofersolan may also enhance intestinal absorption of highly lipophilic medicinal products. Therefore, monitoring should be performed and, when necessary, doses should be adjusted.
Antihistamines, tranylcypromine
The co-administration may enhance and prolong the antimuscarinic and sedative effects of antihistaminic agent
Antihistamines, trazodone [2] ---> SmPC of [2] of eMC
The sedative effects of antihistaminic drugs may be intensified; dosage reduction is recommended in such instance.
Antihistamines, tricyclic antidepressant
Antihistamines potentiate the sedative effects of tricyclic antidepressants
Antihistamines, trihexyphenidyl
Extra care should be taken when trihexyphenidyl is given concomitantly with antihistamines because of the possibility of increased antimuscarinic side-effects.
Antihistamines, tropicamide
Enhancement of anticholinergic effect
Benperidol [1], sedating antihistamines ---> SmPC of [1] of eMC
Benperidol can increase the CNS depression produced by other CNS-depressant drugs
Benzodiazepines, sedating antihistamines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Bromazepam, sedating antihistamines
Enhancement of the depressor effect on the central nervous system
Bromperidol, sedating antihistamines
Bromperidol may enhance the sedation caused by other drugs up to respiratory depression
Brotizolam, sedating antihistamines
The co-administration of brotizolam with other central nervous system depressants may enhance the central nervous depressant effect
Buprenorphine [1], sedating antihistamines ---> SmPC of [1] of EMA
This combination increases central nervous system depression.
Buprenorphine/naloxone [1], sedating antihistamines ---> SmPC of [1] of EMA
The combination increases the central nervous system depression
Bupropion [1], sedating antihistamines ---> SmPC of [1] of eMC
There is an increased risk of seizures occurring with the use of bupropion in the presence of predisposing risk factors which lower the seizure threshold.
Carbamazepine, sedating antihistamines
The co-administration may promote the neurological adverse effects.
Chlordiazepoxide [1], sedating antihistamines ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur if chlordiazepoxide is combined with other CNS-depressant drugs.
Clobazam [1], sedating antihistamines ---> SmPC of [1] of eMC
Especially when clobazam is administered at higher doses, an enhancement of the central depressive effect may occur in cases of combination with other central depressive drugs
Dantrolene, sedating antihistamines
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
Diazepam [1], sedating antihistamines ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur
Dipotassium clorazepate, sedating antihistamines
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
Doxepin, sedating antihistamines
The co-administration may enhance the central sedative effect
Duloxetine [1], sedating antihistamines ---> SmPC of [1] of EMA
Caution is advised when duloxetine is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products
Efavirenz/emtricitabine/tenofovir disoproxil [1], non-sedating antihistamines ---> SmPC of [1] of EMA
Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes
Ethosuximide, sedating antihistamines
Concomitant use of ethosuximide and antihistaminic agents may increase the sedative effects of antihistaminics
Fentanyl [1], sedating antihistamines ---> SmPC of [1] of EMA
The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.
Flunitrazepam, sedating antihistamines
The co-administration may cause a mutual potentiation of effects
Flupentixol, sedating antihistamines [2] ---> SmPC of [2] of eMC
In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.
Fluphenazine [1], sedating antihistamines ---> SmPC of [1] of eMC
Phenothiazines may increase the central nervous system depression produced by other CNS depressants
Flurazepam [1], sedating antihistamines ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Ketamine [1], sedating antihistamines ---> SmPC of [1] of eMC
The use of ketamine with other central nervous system (CNS) depressants can potentiate CNS depression and/or increase risk of developing respiratory depression.
Loprazolam [1], sedating antihistamines ---> SmPC of [1] of eMC
Combination with CNS depressants causes enhancement of the central depressive effects of loprazolam.
Lormetazepam, sedating antihistamines
The benzodiazepines, including lormetazepam produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression
Medazepam, sedating antihistamines
The co-administration of medazepam with other central nervous system depressants may enhance the central nervous depressant effect.
Meprobamate, sedating antihistamines
Meprobamate may increase the effects of concurrently administered central nervous system depressants.
Methadone, sedating antihistamines
The co-administration may have additive psychoactive effects
Metoclopramide, sedating antihistamines
The co-administration may mutually enhance the sedative effects of the CNS. The combination requires caution
Mianserin, sedating antihistamines
Mianserin may enhance the central depressive effect of sedative antihistaminic agent
Midazolam [1], sedating antihistamines ---> SmPC of [1] of EMA
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
Nalbuphine, sedating antihistamines
Other central nervous system depressant drugs may increase the risk of respiratory depression, which can be life-threatening in the case of an overdose
Naltrexone/bupropion [1], sedating antihistamines ---> SmPC of [1] of EMA
Caution should be used when prescribing naltrexone/bupropion to patients with predisposing factors that may increase the risk of seizure
Neuroleptics, sedating antihistamines
The co-administration may cause a mutual potentiation of effects
Nitrazepam, sedating antihistamines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Non-sedating antihistamines, phenylephrine/ketorolac [2] ---> SmPC of [2] of EMA
The magnitude of the mydriatic effect of Omidria may be altered in patients who concurrently receive medicinal products that can affect pupil size, such as opioids (miotics) or non-sedating antihistamines (mydriatics).
Oxazepam, sedating antihistamines
Enhancement of other CNS depressant drugs
Phenobarbital [1], sedating antihistamines ---> SmPC of [1] of eMC
Concurrent administration of phenobarbital with other CNS depressants may lead to an additive CNS depressant effects
Pipamperone, sedating antihistamines
Potentiation of the depressor effect on the CNS
Pipotiazine, sedating antihistamines
The CNS depressant actions of neuroleptic agents may be intensified (additively) by other sedatives. Respiratory depression may occur.
Prazepam, sedating antihistamines
Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects
Quazepam, sedating antihistamines
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Sedating antihistamines, sufentanil
The co-administration may enhance the respiratory depressor effect of sufentanil
Sedating antihistamines, sulpiride
Sulpiride enhances the sedative effect of sedating antihistamine
Sedating antihistamines, tetrazepam
The co-administration may mutually enhance the CNS depressant effects
Sedating antihistamines, tiapride
Enhancement of CNS depressant effect
Sedating antihistamines, tramadol [2] ---> SmPC of [2] of eMC
Concomitant administration of tramadol with other centrally acting drugs may potentiate CNS depressant effects.
Sedating antihistamines, triazolam
Increased CNS depressant effect with the co-administration of triazolam and sedative antihistaminics may occur
Sedating antihistamines, trimipramine [2] ---> SmPC of [2] of eMC
The co-administration of trimipramine with other CNS depressants may increase the CNS depressant effect.
Sedating antihistamines, zaleplon [2] ---> SmPC of [2] of EMA
Combination of zaleplon with other CNS-acting compounds may enhance the central sedation
Sedating antihistamines, zolpidem [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of zolpidem with other central nervous system depressants
Sedating antihistamines, zopiclone [2] ---> SmPC of [2] of eMC
The combination with CNS depressants an enhancement of the central depressive effect may occur.